---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-094886"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2026-08-12T20:14:40+00:00"
generated_at: "2026-08-12T20:16:25.944600+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q2 revenue $7.3M, down 15% YoY; net loss narrows; Genentech partnership signed

## Summary
- Q2 2026 total revenue $7.3M, down 15% YoY; core revenue $6.5M (-21%), SPL revenue $0.8M.
- Net loss $8.9M vs $12.4M loss in Q2 2025; operating expenses down to $15.8M.
- Cash and investments $141.9M at June 30, 2026; repurchased ~$5.5M under $10M program.
- Reiterates FY2026 guidance: revenue $30-32M (core $25-27M, SPL ~$5M); cash ≥$130.5M.
- In July 2026 signed first multi-platform technology license partnership with Genentech.

## SEC filing metadata
- accession: 0001104659-26-094886
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2026-08-12T20:14:40+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000110465926094886/0001104659-26-094886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000110465926094886/mxct-20260812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-094886
- JSON: https://secwatch.observer/filing/0001104659-26-094886.json
- Plain text: https://secwatch.observer/filing/0001104659-26-094886.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.